

## Special Issue

# Bridging Pharmacoepidemiology and Pharmacoeconomics for Better Healthcare Outcomes

### Message from the Guest Editor

The quality use of economic pharmacotherapy has always been a central topic in public health. Randomized controlled trials (RCTs) are the gold standard for drug effectiveness and safety research, whereas the characteristics of RCTs (such as a narrow group of participants, relatively short durations of therapies, and strict implementation of randomization) narrow their external validity when applying the trialed drugs in general populations with diverse characteristics and distinct utilization scenarios. Real-world evidence provides insights beyond those derived from RCTs in medical assessments and clinical practice decisions, along with innovative drug assessment approaches based on pharmacoepidemiology and pharmacoeconomics. Authors are welcome to submit original articles and systematic reviews on the effectiveness, safety, and economic burden of pharmacotherapies based on real-world data. Studies bridging pharmacoepidemiology and pharmacoeconomics are of particular interest to this Special Issue. We look forward to receiving your contributions.

---

### Guest Editor

Dr. Hao Hu

Institute of Chinese Medical Sciences, University of Macau, Macao, China

---

### Deadline for manuscript submissions

closed (31 May 2024)



Pharmacoepidemiology

---

an Open Access Journal  
by MDPI

---

Indexed in Scopus  
Tracked for Impact Factor



[mdpi.com/si/186969](https://mdpi.com/si/186969)

*Pharmacoepidemiology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmacoepidemiology@mdpi.com](mailto:pharmacoepidemiology@mdpi.com)

[mdpi.com/journal/  
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)





**Pharmacoepidemiology**

---

an Open Access Journal  
by MDPI

---

Indexed in Scopus  
Tracked for Impact Factor



[mdpi.com/journal/  
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)



## About the Journal

### Message from the Editor-in-Chief

We are very proud to launch this new, international, peer-reviewed, and open access journal. The main aim of *Pharmacoepidemiology* is to publish novel and up-to-date research findings, reviews, and communications on the beneficial effects of drugs as well as their potential adverse effects on humans through epidemiological studies conducted in the real world on large populations.

All researchers working in the pharmacoepidemiologic field—such as epidemiologists, clinical researchers, pharmacologists, clinicians, and biostatisticians—are welcome to contribute to *Pharmacoepidemiology*.

---

### Editor-in-Chief

Dr. Carlotta Franchi

Laboratory of Pharmacoepidemiology and Human Nutrition,  
Department of Health Policy, Istituto di Ricerche Farmacologiche Mario  
Negri IRCCS, Milan, Italy

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within ESCI (Web of Science), Scopus and other databases.

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.6 days after submission; acceptance to publication is undertaken in 3.2 days (median values for papers published in this journal in the first half of 2025).